Discovery of a Novel Class of Triazolones as Checkpoint Kinase Inhibitors-Hit to Lead Exploration.
Oza, V., Ashwell, S., Brassil, P., Breed, J., Deng, C., Ezhuthachan, J., Haye, H., Horn, C., Janetka, J., Lyne, P., Newcombe, N., Otterbien, L., Pass, M., Read, J.A., Roswell, S., Su, M., Toader, D., Yu, D., Yu, Y., Valentine, A., Webborn, P., White, A., Zabludoff, S., Zheng, X.(2010) Bioorg Med Chem 20: 5133
- PubMed: 20673630 
- DOI: https://doi.org/10.1016/j.bmcl.2010.07.015
- Primary Citation of Related Structures:  
2X8D, 2X8E, 2X8I - PubMed Abstract: 
Checkpoint Kinase-1 (Chk1, CHK1, CHEK1) is a Ser/Thr protein kinase that mediates cellular responses to DNA-damage. A novel class of Chk1 inhibitors, triazoloquinolones/triazolones (TZ's) was identified by high throughput screening. The optimization of these hits to provide a lead series is described.
Organizational Affiliation: 
AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA. Vibha.Oza@astrazeneca.com